Cancer concerns with topical immunomodulators in atopic dermatitis: Overview of data and recommendations to clinicians

American Journal of Clinical Dermatology

Volumn 8, Issue 4, 2007, Pages 189-194

  Patel, Tejesh S ^a   Greer, Sarah C ^a   Skinner Jr , Robert B ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIMETHYLBENZ[A]ANTHRACENE; PHORBOL 13 ACETATE 12 MYRISTATE; PIMECROLIMUS; TACROLIMUS;

ATOPIC DERMATITIS; B CELL LYMPHOMA; BASAL CELL CARCINOMA; CARCINOGENESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA DAMAGE; DRUG APPROVAL; DRUG POTENTIATION; DRUG SAFETY; DRUG USE; HISTIOCYTIC LYMPHOMA; HUMAN; LAMELLAR ICHTHYOSIS; MELANOMA; NETHERTON DISEASE; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SARCOMA; SEZARY SYNDROME; SQUAMOUS CELL CARCINOMA;

ADMINISTRATION, TOPICAL; ANIMALS; CARCINOGENICITY TESTS; DERMATITIS, ATOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA; MODELS, ANIMAL; SKIN NEOPLASMS; TACROLIMUS; ULTRAVIOLET RAYS;

EID: 34547579870     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200708040-00001     Document Type: Review

References (41)

1. Berger TG, Duvic M, Van Voorhees AS, et al. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. J Am Acad Dermatol 2006 May; 54 (5): 818-23
2. Barneston RS, Rogers M. Childhood atopic eczema. BMJ 2002 Jun; 324 (7350): 1376-9
3. Leung DY, Nicklas RA, Li JT, et al. Disease management of atopic dermatitis: an updated practice parameter. Joint Task Force on Practice Parameters. Ann Allergy Asthma Immunol 2004 Sep; 93 (3 Suppl. 2): 1S-21S
4. Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. Allergy 2006 Aug; 61 (8): 969-87
5. Hultsch T, Kapp A, Spergel J. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology 2005; 211 (2): 174-87
6. Leung DY, Boguniewicz M, Howell MD, et al. New insights into atopic dermatitis. J Clin Invest 2004; 113 (5): 651-7
7. Allam JP, Novak N. The pathophysiology of atopic eczema. Clin Exp Dermatol 2006 Jan; 31 (1): 89-93
8. Novak N, Bieber T. The role of dendritic cell subtypes in the pathophysiology of atopic dermatitis. J Am Acad Dermatol 2005 Aug; 53 (2 Suppl. 2): 171S-6S
9. Ring J, Barker J, Behrendt H, et al. Review of the potential photo-cocarcinogenicity of topical calcineurin inhibitors: position statement of the European Dermatology Forum. J Eur Acad Dermatol Venereol 2005 Nov; 19 (6): 663-71
10. Sauder DN. Mechanism of action and emerging role of immune response modifier therapy in dermatologic conditions. J Cutan Med Surg 2004; 8 (3 Suppl.): 3-12
11. Norris DA. Mechanisms of action of topical therapies and the rationale for combination therapy. J Am Acad Dermatol 2005 Jul; 53 (1 Suppl. 1): 17S-25S
12. Wooltorton E. Eczema drugs tacrolimus (Protopic) and pimecrolimus (Elidel): cancer concerns. CMAJ 2005 Apr; 172 (9): 1179-80
13. Novartis Pharmaceuticals Corp. Elidel [package insert]. East Hanover (NJ): Novartis Pharmaceuticals Corp., 2006 Jan 19 [online]. Available from URL: http://www.fda.gov/cder/foi/label/2006/021302s0111b1.pdf [Accessed 2006 Aug 30]
14. Astellas Pharma US Inc. Protopic [package inset]. Deerfield (IL): Astellas Pharma US Inc., 2006 [online]. Available from URL: http://www.fda.gov/ cder/drμg/infopage/protopic/MG_20060119.pdf [Accessed 2006 Aug 30]
15. Panhans-Gross A, Novak N, Kraft S, et al. Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506). J Allergy Clin Immunol 2001; 107 (2): 345-52
16. Wollenberg A, Sharma S, von Bubnoff D, et al. Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis. J Allergy Clin Immunol 2001; 107 (3): 519-25
17. Hoetzenecker W, Meingassner JG, Ecker R, et al. Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhan cells. J Invest Dermatol 2004; 122 (3): 673-84
18. Novartis and Fujisawa FDA briefing statements: Pediatric Advisory Committee Meeting of the US Food Drug Administration, Washington, DC, 2005 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/05/briefing/ 2005-4089b2.htm [Accessed 2006 Oct 1]
19. Jonas S, Rayes N, Neumann U, et al. De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. Cancer 1997 Sep 15; 80 (6): 1141-50
20. Callen J, Chamlin S, Eichenfield LF, et al. A systemic review of the safety of topical therapies for atopic dermatitis. Br J Dermatol 2007; 156 (2): 203-21
21. Harper J, Smith C, Rubins A, et al. A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis. J Invest Dermatol 2005 Apr; 124 (4): 695-9
22. Sotor NA, Fleischer AB Jr, Webster GF, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II. Safety. J Am Acad Dermatol 2001 Jan; 44 (1 Suppl.): 39S-46S
23. Allen BR, Lakhanpaul M, Morris A, et al. Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child 2003 Nov; 88 (11): 969-73
24. Harper J, Green A, Scott G, et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol 2001 Apr; 144 (4): 781-7
25. Draelos Z, Nayak A, Pariser D, et al. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison. J Am Acad Dermatol 2005 Oct; 53 (4): 602-9
26. Ormerod AD. Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern? Br J Dermatol 2005 Oct; 153 (4): 701-5
27. Papp KA, Breuer K, Meurer M, et al. Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. Am Acad Dermatol 2005 Feb; 52 (2): 247-53
28. Stiehm E, Roberts R, Kaplan M, et al. Pneumococcal seroconversion after vaccination for children with atopic dermatitis treated with tacrolimus ointment. J Am Acad Dermatol 2005 Aug; 53 (2 Suppl. 2): 206S-13S
29. Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002; 110: e2 [online]. Available from URL: http://www.pediatrics.org/cgi/ content/full/110/1/e2 [Accessed 2006 Oct 7]
30. Reitamo S, Wollenberg A, Schopf E, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis: the European Tacrolimus Ointment Study Group. Arch Dermatol 2000 Aug; 136 (8): 999-1006
31. Allen A, Siegfried E, Silverman R, et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol 2001 Jun; 137 (6): 747-50
32. Allen DM, Esterly NB. Significant systemic absorption of tacrolimus after topical application in a patient with lamellar ichthyosis. Arch Dermatol 2002 Sep; 138 (9): 1259-60
33. Oji V, Beljan G, Beier K, et al. Topical pimecrolimus: a novel therapeutic option for Netherton syndrome. Br J Dermatol 2005 May; 153 (5): 1067-8
34. Simon GA, Maibach HI. Relevance of hairless mouse as an experimental model of percutaneous penetration in man. Skin Pharmacol Appl Skin Physiol 1998 Mar-Apr; 11 (2): 80-6
35. Richardson K. Labeling changes for the topical calcineurin inhibitors: an expert interview with Mark Lebwohl, MD [online]. Available from URL: http://www.medscape.com/viewarticle/527614 [Accessed 2006 Oct 1]
36. Jiang H, Yamamoto S, Nishikawa K, et al. Anti-tumor-promoting action of FK506, a potent immunosuppressive agent. Carcinogenesis 1993 Jan; 14 (1): 67-71
37. Niwa Y, Terashima T, Sumi H. Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin. Br J Dermatol 2003 Nov; 149 (5): 960-7
38. Tran C, Lubbe J, Sorg O, et al. Topical calcineurin inhibitors decrease the production of UVB-induced thymine dimers from hairless mouse epidermis. Dermatology 2005; 211 (4): 341-7
39. James WD, Berger TG, Elston DM. Andrews' diseases of the skin: clinical dermatology. 10th ed. Philadelphia (PA): Saunders Elsevier, 2006
40. Temeck J. Protopic and Elidel presentation for regulatory briefing on January 14, 2005 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ ac/05/briefing/2005-4089b2_01_02_DPDD%20Consult.pdf [Accessed 2006 Sep 22]
41. Stern RS. Topical calcineurin inhibitors labeling: putting the 'box' in perspective. Arch Dermatol 2006; 142: 1233-4